Table 3.
Anthropometric and Metabolic Parameters in Metabolic Substudy Participants by HIV Status and Use of HAARTa,b
| Parameter | HIV-Uninfected
(N=88) |
HIV-Infected,
Antiretroviral-naïve (N=31) |
HIV-Infected,
on non-PI HAART (N=34) |
HIV-Infected,
on PI-HAART (N=68) |
|---|---|---|---|---|
| Anthropometric measurements | ||||
| Body mass index, kg/m2 | 31.1±0.7 | 29.7±1.4 | 27.0±0.8c | 28.2±0.6c |
| Waist circumference, cm d | 95.1±1.4 | 93.4±2.9 | 88.8±1.9 | 92.6±1.5 |
| Hip circumference, cm d | 108.4±1.2 | 103.3±3.1 | 101.4±1.9 | 104.0±1.5 |
| Waist-hip ratio d | 0.88±0.01 | 0.91±0.01 | 0.88±0.01 | 0.90±0.01 |
| Fasting plasma measurements | ||||
| Glucose level, mg/dL | 98.4±3.6 | 92.4±2.4 | 96.2±4.0 | 90.3±1.9 |
| Insulin level, μU/mL | 15.8±1.2 | 15.3±1.9 | 17.6±2.3 | 16.3±1.5 |
| HOMA-IR, μU/mL·mmol/L | 4.10±0.44 | 3.62±0.50 | 4.50±0.74 | 3.85±0.41 |
| Oral glucose tolerance test | ||||
| Glucose level at 30 min, mg/dL d | 150.0±4.8 | 132.1±5.2 | 144.1±5.2 | 139.0±3.6 |
| Insulin level at 30 min, μU/mL d | 84.0±6.8 | 88.9±13.5 | 114.3±14.8 | 104.0±10.9 |
| Glucose level at 120 min, mg/dL | 117.1±6.2 | 105.5±8.4 | 111.2±5.3 | 109.1±3.4 |
| ΔI30/ΔG30 (μU/mL·mg/dL -1) d | 1.65±0.17 | 2.28±0.45 | 2.45±0.47 | 2.09±0.33 |
| Impaired Glucose Tolerance, N (%) | 8 (9) | 1 (3) | 9 (26)e | 8 (12) |
| Diabetes, N (%) | 7 (8) | 2 (6) | 1 (3) | 3 (4) |
a
HAART, highly active antiretroviral therapy; HOMA-IR, homeostasis model assessment insulin resistance; ΔI30/ΔG30, incremental ratio of insulin to glucose at 30 min
b
Data are mean ± standard error unless otherwise indicated
c
P< .05 compared to HIV-uninfected women; ANOVA
d
Data missing for waist circumference (n=2), hip circumference (n=2), waist-hip ratio (n=3), 30 min insulin level (n=2), 30 min glucose level (n=1), ΔI30/ΔG30 (n=10)
e
P< .05 compared to HIV-uninfected women; Fisher’s exact test